Annual EBIT:
-$504.55M+$37.91M(+6.99%)Summary
- As of today, RARE annual earnings before interest & taxes is -$504.55 million, with the most recent change of +$37.91 million (+6.99%) on December 31, 2024.
- During the last 3 years, RARE annual EBIT has fallen by -$80.99 million (-19.12%).
- RARE annual EBIT is now -7569.02% below its all-time high of -$6.58 million, reached on December 31, 2011.
Performance
RARE EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBIT:
-$107.89M+$35.05M(+24.52%)Summary
- As of today, RARE quarterly earnings before interest & taxes is -$107.89 million, with the most recent change of +$35.05 million (+24.52%) on June 30, 2025.
- Over the past year, RARE quarterly EBIT has increased by +$8.47 million (+7.28%).
Performance
RARE Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBIT:
-$505.09M+$8.47M(+1.65%)Summary
- As of today, RARE TTM earnings before interest & taxes is -$505.09 million, with the most recent change of +$8.47 million (+1.65%) on June 30, 2025.
- Over the past year, RARE TTM EBIT has increased by +$43.76 million (+7.97%).
Performance
RARE TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
RARE EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +7.0% | +7.3% | +8.0% |
| 3Y3 Years | -19.1% | +23.8% | -7.3% |
| 5Y5 Years | -26.7% | -71.1% | -53.8% |
RARE EBIT Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -19.1% | +23.4% | at high | +52.1% | at high | +24.9% |
| 5Y | 5-Year | -231.8% | +23.4% | -114.4% | +52.1% | -66.8% | +24.9% |
| All-Time | All-Time | -7569.0% | +23.4% | >-9999.0% | +52.1% | >-9999.0% | +24.9% |
RARE EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$107.89M(+24.5%) | -$505.09M(+1.6%) |
| Mar 2025 | - | -$142.94M(-16.9%) | -$513.57M(+4.2%) |
| Dec 2024 | -$504.55M(+7.0%) | -$122.28M(+7.4%) | -$535.97M(-0.0%) |
| Sep 2024 | - | -$131.99M(-13.4%) | -$535.74M(+2.4%) |
| Jun 2024 | - | -$116.36M(+29.6%) | -$548.85M(+5.4%) |
| Mar 2024 | - | -$165.35M(-35.5%) | -$580.45M(-2.0%) |
| Dec 2023 | -$542.46M(+17.6%) | -$122.05M(+15.9%) | -$569.21M(+4.0%) |
| Sep 2023 | - | -$145.10M(+1.9%) | -$592.79M(+11.9%) |
| Jun 2023 | - | -$147.96M(+4.0%) | -$672.76M(-1.0%) |
| Mar 2023 | - | -$154.10M(-5.8%) | -$666.39M(-2.7%) |
| Dec 2022 | -$658.71M(-55.5%) | -$145.63M(+35.3%) | -$648.92M(-7.1%) |
| Sep 2022 | - | -$225.07M(-59.0%) | -$605.86M(-28.7%) |
| Jun 2022 | - | -$141.59M(-3.6%) | -$470.62M(-14.3%) |
| Mar 2022 | - | -$136.63M(-33.2%) | -$411.80M(-7.9%) |
| Dec 2021 | -$423.56M(-178.5%) | -$102.56M(-14.2%) | -$381.74M(-5.4%) |
| Sep 2021 | - | -$89.83M(-8.5%) | -$362.05M(-12.3%) |
| Jun 2021 | - | -$82.78M(+22.3%) | -$322.54M(-6.5%) |
| Mar 2021 | - | -$106.57M(-28.6%) | -$302.82M(+4.4%) |
| Dec 2020 | -$152.07M(+61.8%) | -$82.88M(-64.7%) | -$316.92M(+3.5%) |
| Sep 2020 | - | -$50.31M(+20.2%) | -$328.49M(+17.1%) |
| Jun 2020 | - | -$63.05M(+47.7%) | -$396.20M(+11.1%) |
| Mar 2020 | - | -$120.67M(-27.8%) | -$445.62M(-5.1%) |
| Dec 2019 | -$398.31M(-102.1%) | -$94.45M(+20.0%) | -$424.17M(-1.0%) |
| Sep 2019 | - | -$118.03M(-4.9%) | -$420.06M(-7.2%) |
| Jun 2019 | - | -$112.47M(-13.4%) | -$391.67M(-4.7%) |
| Mar 2019 | - | -$99.21M(-9.8%) | -$374.10M(-0.7%) |
| Dec 2018 | -$197.10M | -$90.34M(-0.8%) | -$371.37M(+0.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$89.65M(+5.5%) | -$371.87M(-1.6%) |
| Jun 2018 | - | -$94.90M(+1.6%) | -$365.93M(-4.7%) |
| Mar 2018 | - | -$96.49M(-6.2%) | -$349.48M(-8.2%) |
| Dec 2017 | -$318.34M(-28.4%) | -$90.83M(-8.5%) | -$322.94M(-6.7%) |
| Sep 2017 | - | -$83.71M(-6.7%) | -$302.66M(-6.3%) |
| Jun 2017 | - | -$78.44M(-12.1%) | -$284.73M(-7.7%) |
| Mar 2017 | - | -$69.95M(+0.8%) | -$264.34M(-6.6%) |
| Dec 2016 | -$248.01M(-67.9%) | -$70.55M(-7.2%) | -$248.01M(-6.2%) |
| Sep 2016 | - | -$65.78M(-13.3%) | -$233.62M(-12.4%) |
| Jun 2016 | - | -$58.05M(-8.3%) | -$207.77M(-15.5%) |
| Mar 2016 | - | -$53.62M(+4.5%) | -$179.86M(-21.7%) |
| Dec 2015 | -$147.74M(-160.2%) | -$56.16M(-40.6%) | -$147.74M(-36.1%) |
| Sep 2015 | - | -$39.94M(-32.5%) | -$108.52M(-28.5%) |
| Jun 2015 | - | -$30.14M(-40.2%) | -$84.42M(-24.3%) |
| Mar 2015 | - | -$21.50M(-26.9%) | -$67.94M(-19.7%) |
| Dec 2014 | -$56.78M(-75.9%) | -$16.94M(-7.0%) | -$56.78M(-15.0%) |
| Sep 2014 | - | -$15.84M(-15.9%) | -$49.36M(-19.6%) |
| Jun 2014 | - | -$13.66M(-32.1%) | -$41.29M(-49.5%) |
| Mar 2014 | - | -$10.34M(-8.5%) | -$27.63M(-14.9%) |
| Dec 2013 | -$32.28M(-101.9%) | -$9.53M(-22.7%) | -$24.03M(-25.3%) |
| Sep 2013 | - | -$7.76M(>-9900.0%) | -$19.19M(-19.4%) |
| Jun 2013 | - | $0.00(+100.0%) | -$16.07M(0.0%) |
| Mar 2013 | - | -$6.75M(-44.2%) | -$16.07M(-72.4%) |
| Dec 2012 | -$15.98M(-143.0%) | -$4.68M(-0.8%) | -$9.32M(-100.8%) |
| Sep 2012 | - | -$4.64M(>-9900.0%) | -$4.64M(>-9900.0%) |
| Jun 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2012 | - | $0.00 | $0.00 |
| Dec 2011 | -$6.58M | - | - |
FAQ
- What is Ultragenyx Pharmaceutical Inc. annual earnings before interest & taxes?
- What is the all-time high annual EBIT for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. annual EBIT year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. quarterly earnings before interest & taxes?
- What is the all-time high quarterly EBIT for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. quarterly EBIT year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. TTM earnings before interest & taxes?
- What is the all-time high TTM EBIT for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. TTM EBIT year-on-year change?
What is Ultragenyx Pharmaceutical Inc. annual earnings before interest & taxes?
The current annual EBIT of RARE is -$504.55M
What is the all-time high annual EBIT for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high annual earnings before interest & taxes is -$6.58M
What is Ultragenyx Pharmaceutical Inc. annual EBIT year-on-year change?
Over the past year, RARE annual earnings before interest & taxes has changed by +$37.91M (+6.99%)
What is Ultragenyx Pharmaceutical Inc. quarterly earnings before interest & taxes?
The current quarterly EBIT of RARE is -$107.89M
What is the all-time high quarterly EBIT for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high quarterly earnings before interest & taxes is $0.00
What is Ultragenyx Pharmaceutical Inc. quarterly EBIT year-on-year change?
Over the past year, RARE quarterly earnings before interest & taxes has changed by +$8.47M (+7.28%)
What is Ultragenyx Pharmaceutical Inc. TTM earnings before interest & taxes?
The current TTM EBIT of RARE is -$505.09M
What is the all-time high TTM EBIT for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high TTM earnings before interest & taxes is $0.00
What is Ultragenyx Pharmaceutical Inc. TTM EBIT year-on-year change?
Over the past year, RARE TTM earnings before interest & taxes has changed by +$43.76M (+7.97%)